ijms-logo

Journal Browser

Journal Browser

Antibody Engineering and Therapeutic Applications

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pharmacology".

Deadline for manuscript submissions: 31 January 2026 | Viewed by 3178

Special Issue Editor


E-Mail Website
Guest Editor
Department of Chemistry, Konkuk University, 120 Neungdong-ro, Gwangjin-gu, Seoul 05029, Republic of Korea
Interests: therapeutic antibody; cancer immunotherapy; antibody engineering; structure and mechanism of antibody drugs; protein structure
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Recent advances in antibody-mediated therapies have markedly enhanced their clinical efficacy. Cancer immunotherapy has drastically altered the treatment of multiple types of tumors, leading to the approval of monoclonal antibodies for checkpoint inhibition, CAR-T cell therapies, T-cell engagers, and bispecific antibod-ies. Antibody-drug conjugates (ADCs) represent one of the most swiftly blooming therapeutic modalities in oncology, with 12 ADCs approved by the FDA and over 300 currently undergoing clinical investigations. 

The design and clinical application of monoclonal antibody (mAb) therapeutics ne-cessitate thoroughly comprehending the intricate relationship between their struc-ture and function. Recent breakthroughs in artificial intelligence (AI) methodologies have made significant progress in the generation of protein sequences and struc-tures, enabling the de novo design of antibodies capable of binding to specific sur-faces of target proteins. 

This Special Issue aims to address recent advancements and innovative concepts in the design and application of cutting-edge antibody-mediated therapies, including but not limited to mAb therapeutics, biosimilars, antibody-drug conjugates (ADCs), bispecific and multispecific antibodies, T-cell engagers (TCEs), CAR-T or CAR-NK therapies, nanobodies, immunocytokines, antibody-targeted nanoparticles, antibody structure and mechanism of action, antibody engineering, and AI-driven antibody design. Original papers and review articles are welcome.

Prof. Dr. Yong-Seok Heo
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • monoclonal antibody (mAb) therapies
  • antibody engineering
  • antibody-drug conjugate (ADC)
  • chimeric antigen receptor T cell (CAR-T)
  • bispecific antibody
  • T-cell engager (TCE)
  • cancer immunotherapy
  • immunocytokine
  • AI-driven antibody design
  • antibody structure and mechanism of action

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

15 pages, 1090 KB  
Review
Technologies for Monoclonal Antibody Discovery and Development
by Kyung Ho Han, Yi-Chuan Li, Rabia Parveen, Srimathi Venkataraman and Chih-Wei Lin
Int. J. Mol. Sci. 2025, 26(21), 10470; https://doi.org/10.3390/ijms262110470 - 28 Oct 2025
Viewed by 3012
Abstract
Monoclonal antibodies (mAbs) represent one of the most successful classes of biopharmaceuticals, with more than 100 approved for treating oncological, immunological, and infectious diseases. Antibody discovery and development have been driven by diverse methodologies. Classical strategies such as mouse hybridoma technology, phage display, [...] Read more.
Monoclonal antibodies (mAbs) represent one of the most successful classes of biopharmaceuticals, with more than 100 approved for treating oncological, immunological, and infectious diseases. Antibody discovery and development have been driven by diverse methodologies. Classical strategies such as mouse hybridoma technology, phage display, transgenic mouse models, and single B cell isolation have enabled the generation of high-affinity therapeutic antibodies. Beyond binding affinity, recent innovations in combinatorial antibody libraries have facilitated the selection of functional antibodies within cellular environments, revealing their ability to act as agonists or antagonists and influence signal transduction pathways. These insights expand therapeutic applications by enabling modulation of complex cellular responses. Recent breakthroughs in artificial intelligence, involving antibody generation supported by rapidly growing antibody sequence and structure databases, are transforming computational protein design. This review highlights five major approaches (hybridoma technology, phage display, transgenic mouse models, and single B cell isolation, de novo antibody design) for antibody discovery and development. These approaches offer innovative strategies designed to accelerate the discovery process and enhance therapeutic outcomes for human diseases. Full article
(This article belongs to the Special Issue Antibody Engineering and Therapeutic Applications)
Show Figures

Figure 1

Back to TopTop